心房颤动与冠状动脉疾病:相互作用、结局与演变的管理策略
本综述总结房颤与冠心病共存时的流行病学、病理生理和诊断挑战,并更新治疗决策框架。两者共存形成高风险表型,卒中、急性冠脉综合征、心衰和死亡率显著高于单一疾病,需综合缺血与心律失常风险制定抗栓、节律控制及缺血管理策略。
要点
- 房颤与冠心病共存显著增加卒中、急性冠脉综合征、心衰和死亡风险。
- 两者存在双向交互:房颤加重心肌缺血和内皮功能障碍,冠心病促进心房重构和心律失常。
- 治疗需整合缺血与出血风险,个体化选择抗栓强度、节律控制及缺血管理策略。
核心结论
- 房颤与冠心病共存形成高风险表型,其卒中、急性冠脉综合征、心衰和死亡率显著高于单一疾病。
- 尽管抗栓和节律管理策略有进展,共存患者的诊疗仍具挑战,需基于新证据重新评估管理策略。
研究设计与样本
- 本文为综述,综合现有知识,涵盖流行病学、病理生理、诊断挑战及治疗决策框架。
主要发现
- 两者共存时风险显著高于单一疾病,反映共享合并症和双向交互作用。
- 诊断评估常因症状重叠及生物标志物和影像学混杂而复杂化。
临床怎么用
- 治疗决策需仔细整合缺血和心律失常风险,尤其确定抗栓强度、选择心率或节律控制及管理房颤相关血流动力学下的缺血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atrial fibrillation (AF) and coronary artery disease (CAD) are prevalent cardiovascular disorders that increasingly coexist as populations age and cardiometabolic comorbidities rise. Their intersection creates a high-risk phenotype, with substantially higher rates of stroke, acute coronary syndromes, heart failure and mortality than either condition alone. This excess risk reflects shared comorbidities and complex bidirectional interactions whereby AF exacerbates myocardial ischaemia and endothelial dysfunction and CAD promotes atrial remodelling and arrhythmogenesis.Despite advances in antithrombotic and rhythm management strategies, care for patients with coexisting AF and CAD remains challenging. Diagnostic evaluation is often obscured by overlapping symptoms and confounding biomarker and imaging findings. Therapeutic decisions require careful integration of ischaemic and arrhythmic risk, particularly when determining antithrombotic intensity, selecting rate or rhythm control and managing ischaemia in AF-related haemodynamics. The evidence base has evolved rapidly, with short- and long-term antithrombotic studies and rhythm-control trials reshaping practice, prompting re-evaluation of management strategies.This Review synthesises current knowledge on epidemiology, pathophysiology and diagnostic challenges of AF-CAD coexistence and provides an updated integrated framework for therapeutic decision-making. We discuss contemporary antithrombotic strategies, rate and rhythm control, ischaemia management and clinical outcomes as well as highlight emerging evidence and practical considerations.
引用
- Verburg, Linz, Mohaissen, et al. Atrial fibrillation and coronary artery disease: interactions, outcomes and evolving management strategies. Heart. 2026. PMID: 42785754. doi:10.1136/heartjnl-2026-328218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。